As GMDP Academy students complete their final exams this week, they are closing out an essential phase of their learning journey. We wish them the best of luck as they take this important step! Over the past weeks, they’ve explored the complexities of medicines development—covering everything from lifecycle management to patient engagement and drug safety. While previous updates have highlighted earlier lessons in Module 1, today we’re taking a moment to reflect on the final four sessions (Lessons 7–10) that helped bring this module to a strong conclusion and advance expertise in the field.

Sustaining the Product Lifecycle – Led by Dr. Tamás Sütő

A medicine’s development doesn’t stop at approval—its lifespan must be actively managed to ensure continued availability, efficacy, and value. In this session, Dr. Sütő guided students through the strategic aspects of product lifecycle management, from post-market evidence generation to adapting to regulatory and economic shifts.

Students examined how pharmaceutical companies navigate patent expirations, optimize market access, and plan for new indications—all critical to ensuring medicines remain impactful and accessible to patients.

Clinical Trials Fundamentals and Ethical Considerations – Led by Dr. Domenico Criscuolo

Bringing a medicine from the lab to the market requires rigorous testing and ethical oversight. In this session, Dr. Criscuolo broke down the fundamentals of clinical trials, emphasizing the importance of scientific integrity, patient safety, and regulatory compliance.

Students explored key distinctions between clinical trials and real-world studies, as well as the ethical responsibilities tied to informed consent, data transparency, and patient protection. These principles are the backbone of modern drug development and essential for building public trust in new therapies.

Patient-Centered Medicines Development – Led by Dr. Roz Schneider

A truly effective medicine isn’t just clinically sound—it must also be designed with the patient experience in mind. Dr. Schneider, an expert in human-centered healthcare design, challenged students to consider how patient engagement enhances medical innovation.

The session explored strategies for partnering with patients, caregivers, and communities to ensure medical products align with real-world needs. By embedding patient perspectives into development and decision-making, companies can improve health outcomes, business efficiency, and trust.

Drug Safety and Pharmacovigilance – Led by Dr. Xavier Luria

Ensuring patient safety doesn’t end with clinical trials—it requires ongoing vigilance throughout a drug’s lifecycle. In this session, Dr. Luria introduced students to the principles of pharmacovigilance and risk management, focusing on how adverse events are identified, assessed, and mitigated.

From post-market safety studies to benefit-risk assessments, students learned how regulatory agencies and pharmaceutical companies work together to monitor and improve drug safety over time. This knowledge is essential for anyone involved in protecting patient well-being in a rapidly evolving healthcare landscape.

Why This Matters

The lessons covered in the final stretch of Module 1 are especially relevant in today’s fast-changing healthcare environment.

🔹 Patient-Centered Innovation in Action: The push for patient engagement is reshaping medicine development. Programs like the FDA’s Patient-Focused Drug Development (PFDD) and the use of Patient-Reported Outcome Measures (PROMs) in pediatric care underscore the importance of designing treatments based on real-world patient experiences, improving quality of life and care outcomes.(1, 2)

🔹 The Urgency of Pharmacovigilance: Recent safety concerns, such as those around weight-loss drugs and the long-term effects of COVID-19 treatments, highlight the necessity for ongoing monitoring after a drug is approved. The Pharmacovigilance Risk Assessment Committee (PRAC) is actively assessing safety signals, and this process is essential in identifying adverse events after long-term use.  (3, 4)

🔹 Clinical Trial Ethics in the Spotlight: Transparency in research is more important than ever, with public scrutiny of clinical trials and AI-driven drug development raising ethical questions about data integrity, informed consent, and patient trust. Recent updates to the Declaration of Helsinki have emphasized the need to address emerging ethical challenges posed by AI in health research, such as jurisdictional data governance and the potential harms of AI technologies in clinical trials. These considerations are crucial to ensure that medical research remains ethically sound and respects patient autonomy in an era of rapid technological advancement. (5)

🔹 Global Market Access Challenges: With recent supply chain disruptions and debates over drug pricing and accessibility, understanding how to sustain a medicine’s lifecycle is essential for ensuring that innovation translates into real-world impact for patients worldwide.(6)

Looking Ahead: Module 2 – Medical Affairs and Health Economics

With Module 1 complete, our students are now preparing for Module 2, which begins February 24, 2025. In this next phase, students will dive into Medical Affairs and Health Economics, focusing on the critical aspects of patient access to medicines. Topics will include evidence generation, health economics, and regulatory approval—all pivotal components in the journey from research to commercialization. Digital technologies will also be explored, enhancing the efficiency of evidence generation and enabling better decision-making.

For professionals in medicines development, staying ahead of evolving trends requires both technical proficiency and strategic vision. The GMDP Academy’s certification program offers comprehensive training across the key pillars of the field, including regulatory affairs, clinical trials, and medical affairs. Our program ensures that graduates are prepared to lead and innovate in an ever-changing global healthcare environment.

The insights from Module 1 provide a solid foundation, but the real impact comes from how our students apply this knowledge in the industry. If you’re ready to advance your expertise and make a lasting impact on global healthcare, the GMDP Academy, in partnership with King’s College London, is here to guide you every step of the way.

References

  1. Bele, S., & Santana, M. J. (2025). Patient-reported outcome measures to deliver patient and family-centered care in pediatrics: the ball is now in our court. Frontiers. https://doi.org/10.3389/frhs.2025.1529731
  2. Office of the Commissioner. (2025, January 10). Patient-Focused drug development. U.S. Food And Drug Administration. https://www.fda.gov/about-fda/oncology-center-excellence/patient-focused-drug-development
  3. Zhou, H., Yang, J., Zhang, J., Liu, P., & Yao, D. (2025). A real-world pharmacovigilance analysis of hepatitis B vaccine using the U.S. Vaccine Adverse Event Reporting System (VAERS) database. Nature. https://doi.org/10.1038/s41598-025-90135-8
  4. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 February 2025 | European Medicines Agency (EMA). (2025, February 14). European Medicines Agency (EMA). https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-february-2025
  5. Shaw, J. A. (2024). The revised Declaration of Helsinki—Considerations for the Future of Artificial Intelligence in health and Medical Research. JAMA. https://doi.org/10.1001/jama.2024.22074
  6. Oldfield, L., Penm, J., Mirzaei, A., & Moles, R. (2024). Prices, availability, and affordability of adult medicines in 54 low-income and middle-income countries: evidence based on a secondary analysis. The Lancet Global Health, 13(1), e50–e58. https://doi.org/10.1016/s2214-109x(24)00442-x

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred